LIANG, HONG,ABDICHE, YASMINA NOUBIA,CHAPARRO RIGGERS, JAVIER FERNANDO,GOMES, BRUCE CHARLES,HAWKINS, JULIE JIA LI,PONS, JAUME,QIU, XIAYANG,STROP, PAVEL,WANG, YULI
申请号：
NZ59154109
公开号：
NZ591541A
申请日:
2009.09.11
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is an isolated anti-PCSK9 antibody wherein the antibody recognizes an epitope on human PCSK9 comprising amino acid residues 153-155, 194, 195, 197,237-239,367, 369,374-379 and 381 of the PCSK9 amino acid sequence of Uniprot Accession Number Q8NBP7. Further disclosed are isolated antibodies that comprises a PCSK9 binding region that competes with, or recognizes a first epitope of PCSK9 that overlaps with a second epitope that is recognized by, a monoclonal antibody selected from the group consisting of 5A10, which is produced by a hybridoma cell line deposited with the American Type Culture Collection and assigned accession number PTA-8986； 4A5, which is produced by a hybridoma cell line deposited with the American Type Culture Collection and assigned accession number PTA-8985； 6F6, which is produced by a hybridoma cell line deposited with the American Type Culture Collection and assigned accession number PTA-8984, and 7D4, which is produced by a hybridoma cell line deposited with the American Type Culture Collection and assigned accession number PTA-8983. Further disclosed are isolated antibodies or binding fragments thereof, wherein the antibody comprises a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:8, 59, or 60, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:9 or 61, and a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, or a variant thereof having one or more conservative amino acid substitutions in CDR1 , CDR2, and/or CDR3； and a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:11, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:12, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:13, or a variant thereof having one or more conservative amino acid substitutions in CDR1 , CDR2, and/or CDR3
